Rare diseases
Investigational molecules
Locations
364 conditions with trials, the busiest first
1 206 trials across Europe, recruiting first
Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase
FranceJNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments
FranceLong-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
AustriaStudy of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
AustriaQTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia
FranceAZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma
FranceTreatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia
CzechiaA study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment
AustriaA study of the safety and effectiveness of REGN17372 and linvoseltamab in adults with relapsed or refractory multiple myeloma
GreeceA study to evaluate the effectiveness and safety of efaglomograstim alfa in patients with low blood platelet counts caused by chemotherapy
BulgariaA study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia
CzechiaA study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B
FranceThe therapies tested most often in Blood and lymphatic system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
